Brain Cancer clinical trials in Rhode Island

10 actively recruiting brain cancer trials at 1 site across Rhode Island.

Data from ClinicalTrials.gov · last refreshed 2026-05-25

Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04166409

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …

Sponsor: Children's Oncology Group

NCT ID: NCT05382338

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…

Sponsor: NovoCure GmbH

NCT ID: NCT06556563

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…

Sponsor: InSightec

NCT ID: NCT05317858

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …

Sponsor: Children's Oncology Group

NCT ID: NCT04684368

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05099003

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…

Sponsor: Patrick Wen, MD

NCT ID: NCT02977780

Sites in Rhode Island:

Lifespan / Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual app…

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT06319027

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combi…

Sponsor: Orbus Therapeutics, Inc.

NCT ID: NCT05879367

Sites in Rhode Island:

Brown University Health/Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Rhode Island:

Massive Bio SYNERGY-AI site — Providence, Rhode Island

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25